Sanofi-Aventis (France) Sticks to $69 Per Share Genzyme Corporation Offer

Wall Street Journal -- PARIS (Dow Jones)--French pharmaceuticals giant Sanofi-Aventis SA (SNY.FR) said Thursday it hasn’t made any offers to acquire U.S. biotech group Genzyme Corp. (GENZ) other than its standing all-cash bid of $69 a share.